AN2 Therapeutics
PublicAN2 Therapeutics is now publicly traded
The data on this page reflects AN2 Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Follow-on Offering
Mar 25, 2026
Total Funding Raised
$40M
Company Overview
AN2 Therapeutics (NAS: ANTX) is a biopharmaceutical company focused on developing innovative treatments for rare and serious infectious diseases with significant unmet medical needs.
Sector
Healthcare
AI Layer
Non-AI
Keywords
AN2 Therapeutics Comparables
Compare AN2 Therapeutics with similar companies based on industry and business-model similarity.
No public comparables are available for AN2 Therapeutics. Request access to learn about comparables coverage.
Request accessAN2 Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Mar 25, 2026 |
AN2 Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Coastlands Capital LP | Follow-on Offering |
| Commodore Capital | Follow-on Offering |
| Vivo Capital | Follow-on Offering |
AN2 Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access